GlassScriptPhysician profile
Peter A Nigrovic
NPI 1154388528
$74,647.79
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $8,178 · 2021: $14K · 2022: $19K · 2023: $8,081 · 2024: $4,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,427 · Honoraria: $3,780 · Travel and Lodging: $71.76 · Food and Beverage: $47.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,426.57 |
| Honoraria | $3,780.00 |
| Travel and Lodging | $71.76 |
| Food and Beverage | $47.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $22,055.30 | 2019-2023 | |
| Swedish Orphan Biovitrum Ab | $15,771.02 | 2019-2022 | |
| Pfizer INC. | $14,776.66 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $11,602.89 | 2019-2021 | |
| Alkermes, INC. | $3,600.00 | 2023 | |
| Qiagen, LLC | $3,199.07 | 2023 | |
| Miach Orthopaedics, INC. | $1,800.00 | 2021 | |
| Merck Sharp & Dohme LLC | $1,699.26 | 2023-2024 | |
| Gilead Sciences, INC. | $124.99 | 2019 | |
| Sobi, INC | $18.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Nigrovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.